There's so much more to Johnson & Johnson than you realize. Here are eight facts about the healthcare conglomerate that you may not already be aware of.
You probably missed it, but a big shift is underway in Big Pharma stocks.
Luxury goods maker says the turnaround is under way and only patience is needed to reap the benefits.
GlaxoSmithKline may have surpassed Wall Street's profit expectations in Q2, but unless you really listened to what its management team had to say during the conference call you probably missed a lot of key points. Here are five of them.
Pfizer handily surpassed Wall Street's earnings estimates in the second quarter, but if you didn't dig past the headline numbers, then you likely missed these five important points in the company's conference call.
Pharmaceutical giant Merck may have topped Wall Street's profit expectations in Q2, but these are the really important points that Merck's management team wants its investors to know.
Anyone can buy a household brand-name stock, but sometimes the best gems fly under Wall Street's radar.
Johnson & Johnson topped Wall Street's estimates in Q2, but headline figures usually don't tell you the full story. Here are five key points J&J's management team wants you to take away from its conference call.
Amgen shares soared in July on the heels of three major catalysts. Find out if Amgen has the tools to motor even higher or if you should consider cashing in your chips.
U.K.-based GlaxoSmithKline surpasses Wall Street's profit expectations in the second quarter, and more importantly provides three reasons why investors may be able to stop worrying about its near-term prospects.